(Q34193184)

English

Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting (English)

1 reference

Europe PubMed Central

31 July 2017

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Bin Wu

1

1 reference

Europe PubMed Central

31 July 2017

Baijun Dong

2

1 reference

Europe PubMed Central

31 July 2017

Yuejuan Xu

3

1 reference

Europe PubMed Central

31 July 2017

Qiang Zhang

4

1 reference

Europe PubMed Central

31 July 2017

Jinfang Shen

5

1 reference

Europe PubMed Central

31 July 2017

Huafeng Chen

6

1 reference

Europe PubMed Central

31 July 2017

Wei Xue

7

1 reference

Europe PubMed Central

31 July 2017

language of work or name

0 references

publication date

8 March 2012

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

7

1 reference

Europe PubMed Central

31 July 2017

3

1 reference

Europe PubMed Central

31 July 2017

e32530

1 reference

Europe PubMed Central

31 July 2017

copyright license

Creative Commons Attribution 4.0 International

8 March 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

The Chinese healthcare system: structure, problems and challenges

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

Challenges in developing evidence-based recommendations using the GRADE approach: the case of mental, neurological, and substance use disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

Treatment of metastatic renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

China's health system and its reform: a review of recent studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

EORTC-GU group expert opinion on metastatic renal cell cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

Establishing the role of cytokine therapy in advanced renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

Cytokine therapy: a standard of care for metastatic renal cell carcinoma?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

Lessons learned in the surgical management of renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

Immunotherapy for advanced renal cell cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

Development of WHO guidelines on generalized cost-effectiveness analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

5 July 2018

Renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0032530

21 January 2018

Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0032530

21 January 2018

Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0032530

21 January 2018

How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0032530

21 January 2018

Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0032530

21 January 2018

Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297611

28 October 2018

Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China

1 reference

https://pubmed.ncbi.nlm.nih.gov/22412884

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22412884

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://pubmed.ncbi.nlm.nih.gov/22412884

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Importance of surgical margins in the management of renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22412884

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

1 reference

https://pubmed.ncbi.nlm.nih.gov/22412884

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0032530

1 reference

Europe PubMed Central

31 July 2017

2012PLoSO...732530W

0 references

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34193184&oldid=1868089828"